eligibility_summary
Adults ≥18 with adv/met solid tumors, Phase I: any except glioblastoma, Phase II: NSCLC, GE adenoca, CRC, pancreas, sarcoma, TNBC, ovarian. ≤4 prior lines, measurable disease, ECOG 0–1, contraception. Exclude: recent therapy/surgery or unresolved AEs, QT‑prolonging meds, unstable CNS mets, autoimmune or active infection (HBV/HCV/HIV), major cardiopulmonary/GI disease, transplant or immunosuppression, pregnancy. Phase II PD: baseline and D36–42 fresh biopsies (ovarian/sarcoma exempt).
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: XON7, an intravenous glyco-humanized polyclonal antibody (biologic immunotherapy). Mechanism: multi-epitope antibody derived with human-like glycosylation to reduce immunogenic carbohydrate residues and enhance Fc effector function, expected to mediate tumor cell killing primarily via Fc-dependent mechanisms—antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC). Specific tumor antigen(s) are not disclosed in the record. Target cells/pathways: malignant cells in advanced/metastatic solid tumors (cohorts include NSCLC, gastro-esophageal adenocarcinoma, colorectal, pancreatic, sarcoma, TNBC, ovarian) and immune effector pathways involving Fcγ receptor–bearing cells (NK cells, macrophages, neutrophils) and the classical complement cascade within the tumor microenvironment.